Cargando…
Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
PURPOSE: Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement over the past decades. Aggressive tumor biology or delay in access to cancer care might be contributing factors. With this retrospective population-based stud...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167164/ https://www.ncbi.nlm.nih.gov/pubmed/35461374 http://dx.doi.org/10.1007/s10549-022-06591-7 |
_version_ | 1784720769116274688 |
---|---|
author | Boman, Caroline Edman Kessler, Luisa Bergh, Jonas Matikas, Alexios Foukakis, Theodoros |
author_facet | Boman, Caroline Edman Kessler, Luisa Bergh, Jonas Matikas, Alexios Foukakis, Theodoros |
author_sort | Boman, Caroline |
collection | PubMed |
description | PURPOSE: Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement over the past decades. Aggressive tumor biology or delay in access to cancer care might be contributing factors. With this retrospective population-based study we aimed to quantify and characterize patients with very short survival time following MBC diagnosis. METHODS: Women diagnosed with MBC between Jan 1st, 2005 and Dec 31st, 2016 were identified using the population-based Stockholm–Gotland breast cancer registry. Data regarding demographic and clinicopathological characteristics, survival, and treatment were extracted retrospectively from the registry and from patient charts. Patients who died within 90 days following diagnosis of MBC were identified and their characteristics were compared with all other patients diagnosed with MBC during the same period. RESULTS: Between 2005 and 2016, 3124 patients were diagnosed with MBC, of whom 498 (16.2%) died within 90 days of diagnosis. Nearly half (N = 233) did not receive any antitumoral treatment. Patients with short survival were older (p < 0.001), had higher primary tumor grade (p < 0.001), higher clinical stage at primary diagnosis (p = 0.002), and more often estrogen receptor (ER)-negative breast cancer (p < 0.001). Visceral metastases were more frequent (p < 0.001) and patients with short survival received adjuvant chemotherapy (p < 0.001) to a lesser extent compared to patients with a better prognosis. In multivariable analysis older age, time period of diagnosis, metastasis site, adjuvant chemotherapy, and primary tumor grade were independent predictors for short survival, whereas ER status was not. CONCLUSION: Nearly one out of six patients with MBC survive less than 3 months after diagnosis. Our findings demonstrate a different spectrum of MBC at population level and can potentially inform on individualized follow-up strategies and treatment algorithms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06591-7. |
format | Online Article Text |
id | pubmed-9167164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-91671642022-06-06 Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study Boman, Caroline Edman Kessler, Luisa Bergh, Jonas Matikas, Alexios Foukakis, Theodoros Breast Cancer Res Treat Clinical Trial PURPOSE: Despite therapeutic advances, overall survival of metastatic breast cancer (MBC) at the population level has seen little improvement over the past decades. Aggressive tumor biology or delay in access to cancer care might be contributing factors. With this retrospective population-based study we aimed to quantify and characterize patients with very short survival time following MBC diagnosis. METHODS: Women diagnosed with MBC between Jan 1st, 2005 and Dec 31st, 2016 were identified using the population-based Stockholm–Gotland breast cancer registry. Data regarding demographic and clinicopathological characteristics, survival, and treatment were extracted retrospectively from the registry and from patient charts. Patients who died within 90 days following diagnosis of MBC were identified and their characteristics were compared with all other patients diagnosed with MBC during the same period. RESULTS: Between 2005 and 2016, 3124 patients were diagnosed with MBC, of whom 498 (16.2%) died within 90 days of diagnosis. Nearly half (N = 233) did not receive any antitumoral treatment. Patients with short survival were older (p < 0.001), had higher primary tumor grade (p < 0.001), higher clinical stage at primary diagnosis (p = 0.002), and more often estrogen receptor (ER)-negative breast cancer (p < 0.001). Visceral metastases were more frequent (p < 0.001) and patients with short survival received adjuvant chemotherapy (p < 0.001) to a lesser extent compared to patients with a better prognosis. In multivariable analysis older age, time period of diagnosis, metastasis site, adjuvant chemotherapy, and primary tumor grade were independent predictors for short survival, whereas ER status was not. CONCLUSION: Nearly one out of six patients with MBC survive less than 3 months after diagnosis. Our findings demonstrate a different spectrum of MBC at population level and can potentially inform on individualized follow-up strategies and treatment algorithms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06591-7. Springer US 2022-04-24 2022 /pmc/articles/PMC9167164/ /pubmed/35461374 http://dx.doi.org/10.1007/s10549-022-06591-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Trial Boman, Caroline Edman Kessler, Luisa Bergh, Jonas Matikas, Alexios Foukakis, Theodoros Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
title | Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
title_full | Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
title_fullStr | Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
title_full_unstemmed | Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
title_short | Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
title_sort | women with short survival after diagnosis of metastatic breast cancer: a population-based registry study |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167164/ https://www.ncbi.nlm.nih.gov/pubmed/35461374 http://dx.doi.org/10.1007/s10549-022-06591-7 |
work_keys_str_mv | AT bomancaroline womenwithshortsurvivalafterdiagnosisofmetastaticbreastcancerapopulationbasedregistrystudy AT edmankesslerluisa womenwithshortsurvivalafterdiagnosisofmetastaticbreastcancerapopulationbasedregistrystudy AT berghjonas womenwithshortsurvivalafterdiagnosisofmetastaticbreastcancerapopulationbasedregistrystudy AT matikasalexios womenwithshortsurvivalafterdiagnosisofmetastaticbreastcancerapopulationbasedregistrystudy AT foukakistheodoros womenwithshortsurvivalafterdiagnosisofmetastaticbreastcancerapopulationbasedregistrystudy |